A new method of inducing immune tolerance for haplotype hematopoietic stem cell transplantation in the treatment of severe aplastic anemia

doi:10.3969/j.issn.2095-4344.2015.41.022

Abstract

Abstract:

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective mean to cure severe aplastic anemia, and especially haplotype transplantation is regarded as a transplantation system with Chinese characteristics, and rank at the international leading level.
OBJECTIVE: To explore the patterns of haplotype allo-HSCT as a new immune tolerance method for severe aplastic anemia and to solve the transplantation rejection and graft-versus-host disease.
METHODS: Twelve patients with severe aplastic anemia who underwent haplotype allo-HSCT at the Department of Hematology, General Hospital of Beijing Military Area, China from April 2013 to May 2014 were enrolled. All
these patients received the new regimen of inducing immune tolerance through the application of high-dose cyclophosphamide (400 mg/m2, consecutively 3 days before transplantation; 50 mg/kg, consecutively 3 days after haplotype transplantation).
RESULTS AND CONCLUSION: The median time of neutrophil recovery was 17 (13-21) days, and the median time of platelet recovery was 21 (15-31) days. After transplantation, there were one case of degree II acute graft-versus-host disease and one case of chronic graft-versus-host disease, both of which were controlled. The follow-up time was 6 months at least, and the median time was 11 months. During the follow-up, one case died of rejection reaction and one case died of severe lung infection. These findings indicate that the new method of inducing immune tolerance with high-dose cyclophosphamide after transplantation for severe aplastic anemia has significant effects in reducing graft-versus-host disease and transplantation-related mortality rate.
中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Anemia, Aplastic, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Immune Tolerance, Tissue Engineering

Guo Zhi, Chen Hui-ren, Yang Kai, Liu Xiao-dong, Lou Jin-xing, He Xue-peng. A new method of inducing immune tolerance for haplotype hematopoietic stem cell transplantation in the treatment of severe aplastic anemia[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(41): 6683-6687.

Figures/Tables 2

References

[1] Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12): 1784-1791.

[2] Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev. 2013;7: CD006407.

[3] 郭智,陈惠仁,何学鹏,等.单倍型异基因造血干细胞移植治疗儿童难治性或复发白血病30例[J].中华器官移植杂志,2013,34(1): 33-36.

[4] 郭智,陈惠仁,刘晓东,等.单倍型异基因造血干细胞移植治疗儿童重型再生障碍性贫血[J].中华实用儿科临床杂志,2014,29(15): 1145-1148.

[5] Lee YH, Kim JY, Choi BO, et al. Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia. Radiat Oncol J. 2012;30(4): 165-172.

[6] 陈惠仁.单倍型造血干细胞移植的新进展及其临床结果[J].中国组织工程研究,2008,12(34): 6735-6738.

[7] Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12): 1835-1844.

[8] 闫洪敏,王志东,朱玲,等.多种来源造血干细胞移植治疗重型再生障碍性贫血[J].中国组织工程研究与临床康复,2011,15(10): 1884-1888.

[9] 孙璨,林遐,黄宇贤,等.采用含氟达拉滨的增强预处理异基因造血干细胞移植治疗22例重型再生障碍性贫血患者的临床研究[J].中华血液学杂志,2014,35(3):221-224.

[10] 陆婧媛,鹿全意,林进宗,等.单倍体相合造血干细胞移植治疗儿童重型再生障碍性贫血[J].中国组织工程研究,2014,18(23):3768- 3772.

[11] Chun C, Fang JP, Xue HM, et al. Allogeneic hematopoietic stem cell transplantation for childhood aplastic anemia: prospective trial in China. Transfus Apher Sci. 2011;44(1):41-47.

[12] Sun ZM, Liu HL, Geng LQ, et al. HLA-matched sibling transplantation with G-CSF mobilized PBSCs and BM decreases GVHD in adult patients with severe aplastic anemia. J Hematol Oncol. 2010;3:51.

[13] 陈惠仁,楼金星,张媛,等.非血缘HLA相合供者造血干细胞移植治疗重型再生障碍性贫血的临床分析[J].中国实验血液学杂志, 2012, 20(4): 959-964.

[14] 韩伟,黄晓军,刘开彦,等.配型不合造血干细胞移植治疗重型再生障碍性贫血的疗效及安全性[J].中华内科杂志,2011,50(4): 287-290.

[15] Esteves I, Bonfim C, Pasquini R, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685-689.

[16] 陈晓霞,王智明,罗贤生,等.改良BU/CY预处理方案在外周血造血干细胞移植中的临床应用[J].中国组织工程研究,2010,14(14): 2638-2642.

[17] Hutspardol S, Sirachainan N, Anurathapan U, et al. Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia. J Med Assoc Thai. 2013;96 Suppl 1: S18-24.

[18] Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15): 3447-3454.

[19] Xu LP, Liu KY, Liu DH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012;47(12):1507-1512.

[20] Im HJ, Koh KN, Suh JK, et al. Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients. Bone Marrow Transplant. 2015;50(2): 225-231.

Gao L, Li Y, Zhang Y, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49(4):519-524.